Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CHAD vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBIO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–3 Matrix Metrics)

ZBIO Overall Winner 6-Pillar Tally: CHAD 0 – 4 ZBIO (2 Tie) Matrix Metrics: CHAD 3 – 5 ZBIO

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over CHAD (CHAD) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CHAD carries a Unified Composite Score of 50.9/100 (HOLD) at $10.00 (N/M Forward P/E, N/A operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Composite vs. Pillar Nuance: While CHAD currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. ZBIO 49.4/100 HOLD), ZBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2747.5% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: CHAD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHAD vs ZBIO
CHAD US Equity
CHAD
Institutional Equity
$10.00
+0.21% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 11% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ZBIO NASDAQ Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (CHAD 0 – 4 ZBIO)

Columns: Metric · CHAD · ZBIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ZBIO
Revenue Growth (YoY) N/A -100.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $11M
Market Cap N/A $1.9B
3. Profitability & Quality ZBIO
Gross Margin N/A N/A
Operating Margin N/A -2747.5%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -265.1%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) N/A -$273M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 103.9% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHAD (3) vs ZBIO (5)
Institutional Metric CHAD ZBIO Criterion Row Edge
Market Capitalization
Scale
N/A $1.9B Larger Scale ZBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -100.0% Higher Growth ZBIO
Operating Margin (TTM)
Profitability
N/A -2747.5% Higher Margin ZBIO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ZBIO
Return on Equity (ROE)
Capital Efficiency
N/A -265.1% Higher ROE ZBIO
52-Week Range Position
Momentum
100% ($7–$10) 46% ($14–$45) Stronger Trend CHAD
Beta / 30D Volatility
Risk Regime
0.71β · 11% Vol 1.16β · 59% Vol Lower Realized Risk CHAD
Unified Institutional Score
Composite Signal
50.9 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite CHAD
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +5.37 pp
CHAD: +7.07% · ZBIO: +12.44%
3M Horizon CHAD +35.11 pp
CHAD: +19.62% · ZBIO: -15.49%
6M Horizon CHAD +35.11 pp
CHAD: +19.62% · ZBIO: -15.49%
1Y Horizon CHAD +35.11 pp
CHAD: +19.62% · ZBIO: -15.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHAD vs ZBIO. Trailing 12-month operating profitability (CHAD N/A vs ZBIO -2747.5%) and valuation multiples (CHAD N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CHAD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ZBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-2747.5%
ROE / Fwd P/E-265.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHAD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHAD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CHAD vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over CHAD (CHAD) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CHAD carries a Unified Composite Score of 50.9/100 (HOLD) at $10.00 (N/M Forward P/E, N/A operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Composite vs. Pillar Nuance: While CHAD currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. ZBIO 49.4/100 HOLD), ZBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2747.5% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY). Technical & Structure Timing Caution: CHAD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZBIO leads the Growth & Scale pillar: CHAD posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). On trailing 12-month operating scale, CHAD generates N/A in USD-normalized revenue versus $11M for ZBIO. In operating R&D and SG&A reinvestment, CHAD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

CHAD and ZBIO trade at balanced relative valuation multiples. CHAD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHAD (N/A ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CHAD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 11% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.